Small molecular inhibitors targeting Janus kinases (JAKs) for the treatment of psoriasis
Authors:
- 26 June 2025
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117904
Abstract
No abstract availableKeywords
This publication has 178 references indexed in Scilit:
- Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in PsoriasisJAMA Dermatology, 2024
- Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro ProfilingArthritis & Rheumatology, 2023
- JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and managementAmerican Journal of Hematology, 2023
- Isothermal Titration Calorimetry2021
- Itaconic acid derivatives: structure, function, biosynthesis, and perspectivesApplied Microbiology and Biotechnology, 2020
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- The Effect of Renal Impairment on the Pharmacokinetics and Safety of ItacitinibThe Journal of Clinical Pharmacology, 2020
- Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesJournal of Cellular Physiology, 2020
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled TrialArthritis & Rheumatology, 2019
- In Vitro JAK Kinase Activity and Inhibition Assays2012